Overview
- The team published preclinical results on Sept. 28 showing an AI‑guided platform called AGENT found excipient combinations that stabilize clinically relevant mRNA–lipid nanoparticle (LNP) formulations.
- AGENT screened about 50 FDA‑approved excipients and converged on promising recipes in six iterative rounds over roughly a month, cutting the usual trial‑and‑error time dramatically.
- In animal tests, thermostable LNPs preserved immune responses comparable to a Moderna‑like vaccine in mice and were used to make dissolvable microneedle patches including delivery demonstrated in nonhuman primates.
- The reported stability was approximately one year at room temperature and about two months at 37°C, after vacuum drying, but researchers observed structural changes in reconstituted LNPs that require further study.
- The work remains preclinical and next steps include scaling consistent manufacturing, defining quality metrics for altered LNPs, navigating regulatory review, and integrating related automation technology for precise LNP size control being commercialized by BIZON Labs.